Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance
J Wu, Z Lin - International journal of molecular sciences, 2022 - mdpi.com
The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …
Tumour heterogeneity and resistance to cancer therapies
I Dagogo-Jack, AT Shaw - Nature reviews Clinical oncology, 2018 - nature.com
Cancer is a dynamic disease. During the course of disease, cancers generally become more
heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse …
heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse …
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of …
NI Lindeman, PT Cagle, DL Aisner… - … of pathology & …, 2018 - meridian.allenpress.com
Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …
Pathologists, the International Association for the Study of Lung Cancer, and the Association …
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
[HTML][HTML] Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
Integrating evolutionary dynamics into cancer therapy
RA Gatenby, JS Brown - Nature reviews Clinical oncology, 2020 - nature.com
Many effective drugs for metastatic and/or advanced-stage cancers have been developed
over the past decade, although the evolution of resistance remains the major barrier to …
over the past decade, although the evolution of resistance remains the major barrier to …
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
AN Hata, MJ Niederst, HL Archibald… - Nature medicine, 2016 - nature.com
Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-
mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known …
mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known …
The mathematics of cancer: integrating quantitative models
Mathematical modelling approaches have become increasingly abundant in cancer
research. The complexity of cancer is well suited to quantitative approaches as it provides …
research. The complexity of cancer is well suited to quantitative approaches as it provides …
[HTML][HTML] Classifying the evolutionary and ecological features of neoplasms
Neoplasms change over time through a process of cell-level evolution, driven by genetic
and epigenetic alterations. However, the ecology of the microenvironment of a neoplastic …
and epigenetic alterations. However, the ecology of the microenvironment of a neoplastic …
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical
benefit in patients with advanced EGFR-mutant (EGFRm+) non–small cell lung cancer …
benefit in patients with advanced EGFR-mutant (EGFRm+) non–small cell lung cancer …